Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Earlier, Novo Nordisk cut the sale and profit forecast for the first time since Wegovy’s release four years ago.
Wegovy-Maker Novo Nordisk, CEO Lars Frugenaard Jorgensen, the company’s highly competitive obesity in the drug market has lost its first moviability.
Novo Nordisk announced its decision on Friday.
Days, Yesterday, Novo Nordisk, Jorgensen, Jorgensen forecast for the first time in the second half of this year, forecasting the return of the growth return in the largest market, cut off the sale and profit forecast for the first time.
Nova’s chairman, Helge Lund, analysts and investors tried to convince a call with the intact of the company’s strategy and the implementation plan.
Reuters told the news agency that the discussions on the replacement of Jorgensen had occurred in the last few weeks. Novo said he would stay in his role until Jorgensen had previously found a successor.
Jorgensen was the world leader in the weight-loss medicinal market with skyokating sales of Novo Nordisk, Wegovy and ozemischas of wegovy and ozempic.
Analysts and investors were not sure of the need to replace it.
“He has been for eight years for eight years, in my opinion, it was extremely successful,” he said.
Danske Bank analyst Carsten Lonborg Madsen was also careful.
“The road we know, when we are on the right path, ensure that everything is on the right track, and you allowed the strategy to move in the right direction.
“It feels like something that is quite wrong here,” he said.
Nova’s shares have brought up to their market, especially since the competition, as a record in June last year, especially the U.S. rival Eli Lilly.
“Since mid-2024, Novo Nordisk has been made in the light of the company’s share price for the latest market problems and the company’s stock price,” Novo said.
It shares
Jorgensen in 58, spent CEO since 2017. Denmark said that he did not see the decision on the interview with the broadcaster TV2 and only recently informed.
Wegovy’s development has produced the most valuable company, which is worth $ 615 billion in June last year, but its market value has produced about $ 310 billion.
Novo Nordiskin stock price fell into news, 4.8 percent of the day in the day by 0.8 percent.
Shares 32 percent are 59 percent every year and always high.
Eli Lilly, in the largest market since mid-March, saw our recipes for Zepbound obesity kick. Eli Lilly shares increased by 2.6 percent after the news.
Camilla Sylvest, November’s trade strategy and president of Corporate Affairs and Corporate Affairs and CEO Jorgensen, went down last month without indicating a reason.
Novo Nordisk, Lars Ribien Sorensen Novo Nordisk Foundation Lars Rerien Sorensen, will join the board as an observer to sit at the next annual general meeting.
The company is governed by the Novo Nordisk Foundation via the investment branch, which has 77 percent of voting shares.
